Key information made simple
What the source says
The registry describes this research topic: “Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Risperidone Extended Release Capsules in Patients with Schizophrenia, Schizoaffective Disorder or Bipolar 1 Disorder”. This is an interventional study. The registry lists a target sample size of 8. Recruitment status at the registry update of 2024-10-05: withdrawn. Read the original description and eligibility criteria, and confirm the practical details with the study team.
What should you check before joining?
Check the full criteria in the official source. Ask the team to confirm recruitment, locations, visits, risks and participation requirements.

